Effects of Canagliflozin on the Outcomes of Patients With Type 2 Diabetes in Subgroups of Population-Specific BMI
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetes, Obesity & Metabolism
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial
Diabetes Obes Metab 2023 Sep 06;[EPub Ahead of Print], J Yu, AN Sweeting, C Gianacas, L Houston, V Lee, RA Fletcher, V Perkovic, Q Li, BL Neuen, O Berwanger, HJL Heerspink, D de Zeeuw, C ArnottFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.